HLN Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Sobre Haleon plc American Depositary Shares (Each representing two Ordinary Shares) Visão geral da empresa da Wikipedia

Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England. It is one of the largest consumer healthcare businesses in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers, and Centrum vitamins. The company was projected to be a global leader in over the counter medicines with a 7.3 per cent market share in 2022.

Ler mais

Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England. It is one of the largest consumer healthcare businesses in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers, and Centrum vitamins. The company was projected to be a global leader in over the counter medicines with a 7.3 per cent market share in 2022.

Haleon was established on 18 July 2022 as a corporate spin-off from GSK. Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange.

History

GSK and Pfizer merged their consumer healthcare businesses in 2019. GSK owned just over two thirds of the joint venture, and Pfizer owned the remainder. Annual sales were around £10 billion across 120 markets in 2020. GSK then announced plans to spin off Haleon in 2022 to give the "tired drugmaker extra focus and firepower by gearing up and hiving off the consumer division," according to Reuters. Unilever offered £50 billion for the business in 2022, which GSK rejected. Nestlé examined the possibility of a bid in conjunction with Reckitt. In October 2023, GSK reduced its ownership in Haleon to 7.4%, and in January 2024 it further reduced its ownership to 4.2%.

In August 2023, Haleon sold its Lamisil antifungal brand to Karo Healthcare AB for £235 million, and in February 2024, Haleon sold its ChapStick lip care brand to Yellow Wood Partners for £401 million.

In March 2024, Pfizer reduced its share in Haleon from 32% to 24% per cent by selling 630 million shares in a public offering.

Further sales followed: in April 2024, Haleon announced that it would close its Sensodyne toothpaste factory in Maidenhead, moving that manufacturing to Slovakia, and it outsourced mouthwash manufacturing to an unrelated company and, in September 2024, the company completed the sale of its non-US nicotine replacement therapy business to Dr. Reddy's Laboratories in a deal worth £458 million.

In March 2025, Pfizer sold its entire stake in Haleon for £2.5 billion ($3.24 billion), exiting the consumer healthcare business it helped create by its 2019 joint venture with GSK.

Operations

Oral health accounted for 28.5 percent of revenue in 2021.

Sir Dave Lewis is chairman, with Brian McNamara as chief executive.

Brands

Current

Brands include:

=== Divested ===

Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗

Wikidata ↗

HLN Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas

Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS

Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?

Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC

Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial

Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos

Métricas por Ação EPS, valor patrimonial por ação, fluxo de caixa por ação, dividendo por ação

Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber

Dividendos Rendimento, índice de pagamento, histórico de dividendos, CAGR de 5 anos

HLN Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta

Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados

Últimas notícias Notícias recentes mencionando esta empresa

• Haleon Recalls Certain Gas-X Extra Strength Softgels Nasdaq · 2 meses, 2 semanas atrás

Investidores institucionais (13F) 687 declarantes · $3.8B total · Em 30 de Junho de 2026

Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.

Ativistas e proprietários de 5%+ 2 participações

Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Participação em ETFs Detido por 36 ETFs

O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.